Visible light‐induced solar urticaria is improved by omalizumab

Clinical and photobiological response in eight patients with solar urticaria under treatment with omalizumab, and review of the literature

“…The patient with the most prolonged therapy in our series had 60 months with the medication, and we have observed rapid relapses in patients who terminated therapy. This has also been reported previously . On the other hand, SU may be self‐limiting as spontaneous resolution has been observed in 50 and 70% of patients after 5 and 11 years of follow‐up, respectively …”

“…A total of 16 reports, mostly case reports, a few small case series and one clinical trial were analysed in this review. After including the current case series (with 5 patients not previously reported in the literature), a total of 38 patients were identified, 26 patients (68.4%) responded favourable to omalizumab therapy (complete or partial responses) and 12 did not (31.6%).…”

“…This has also been reported previously. 9,23 On the other hand, SU may be self-limiting as spontaneous resolution has been observed in 50 and 70% of patients after 5 and 11 years of follow-up, respectively. 1 Major strengths of our study are multiple questionnaires as well as self-reporting, used to measure clinical response and the fact that almost all the patients underwent phototesting before and during therapy.…”

Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence

“…Several case reports describe full remission of solar urticaria. 39,41,42,[61][62][63][64][65][66][67] Initial doses in these cases ranged from 150 to 375 mg, although in some patients a higher dose of 450 mg was necessary to achieve complete symptom control. 62,68 Patients often relapsed 2 to 8 weeks after discontinuing treatment but then responded well to the next omalizumab injection.…”

Solar urticaria, a disease with many dark sides: is omalizumab the right therapeutic response? Reflections from a clinical case report

“…Solar urticaria of all chronic induced urticarias sub-types, has the highest number of publications on omalizumab use and the majority show that omalizumab successfully control the disease [10, 11, 12, 13, 14, 15, 16, 17]. Initial doses range from 150 to 375 mg, although in some patients a higher dose of 450 mg is necessary to achieve complete symptom control.…”